Welcome to Marianne N. Broughton's research group:
The Tumormarker Group
Immunoassay techniques have revolutionized the determination of clinically relevant proteins and peptides. The Tumormarker Group at MBK, Radiumhospitalet is one of the few hospital laboratories that still develops, validates and introduces novel “in house” assays into the clinic. We have more than 25 years of experience in the production of monoclonal antibodies (mAbs) for use in the construction of these highly specialized assays. Many of our mAbs have been licensed and are used in the manufacture of commercial assay kits that are in worldwide use. In January 2013 we were assigned a function as Core Facility for monoclonal antibody production and assay design within Helse Sør-øst. The Facility aids researchers in the utilization of monoclonal antibody technology and provides custom monoclonal antibodies reactive to antigens of interest to the individual investigator. The challenges related to immunometric assays, particularly the problems caused by heterophilic antibodies or human anti-mouse antibodies have been thoroughly studied by the group and we have undertaken extensive studies on the incidence and prevention of interference in immunometric assays.
- Developing assays for measuring monoclonal antibodies used in the treatment of patients with autoimmune disease such as rheumatoid arthritis and Crohn's disease. By following serum concentration of these medications the clinicians may be able to optimise the treatment for each individual patient. A collaboration study with the Department of Pharmacology and clinicians at Rikshospitalet and Diakonhjemmet.
- Evaluating the established small cell lung cancer marker progastrin-releasing peptid (proGRP) as a marker for carcinoid tumours of the lung and medullary thyroid cancer.
- Developing immunoassays for human epidermal growth factor receptors 2, 3 and 4 and evaluating these receptors as tumour markers for HER2 positive brest cancer.
- Part of the collaboration study "Hallmarks in lung cancer"; validating different markers for potential development og assays clinically used in daily practice.
- Part of a collaboration study with the Department of Pharmaceutical Chemistry, UiO, where two dimensional chromatography combined with mass spectrometry is used to identify and quantify tumour markers.
Group leader PhD Marianne Nordlund Broughton, Department of Medical Biochemistry Oslo University Hospital, Radiumhospitalet Tel: +47 22934397 E-mail: firstname.lastname@example.org
Early phase drug development: From idea to concept
Feb 3, 2017
Feb 2, 2017
Oncolytic peptide LTX-315; the road from basic science to clinical trials
Jan 26, 2017